Bristol-Myers Squibb buys MyoKardia for $13.1bn

It’s the year’s second-largest pharmaceuticals deal so far.

It’s the year’s second-largest pharmaceuticals deal so far.

In a major move in the heart disease arena, Bristol-Myers Squibb (BMS) has acquired MyoKardia, a drug developer that specializes in cardiovascular diseases, for $13.1 billion in cash.

Based in Brisbane, San Francisco, MyoKardia has one particularly valuable drug under its wing: mavacamten, which aims to treat obstructive hypertrophic cardiomyopathy (HCM), a condition that affects one in every 500 people by thickening the heart wall enough to render blood-pumping inefficient. The company has ambitions for the drug to become its first commercial product; its only obstacle now is FDA (Food and Drug Authority) approval, which it will seek in Q1 2021. If this is obtained, BMS’s commercial infrastructure will be critical in giving mavacamten a strong market presence.

Clearly, Bristol-Myers Squibb’s mammoth purchase of Celgene last year for $74 billion has not dampened the pharma giant’s appetite for strategic acquisitions. It already has some presence in the cardiovascular space: its drug Eliquis is the world’s bestselling orally ingested blood thinner.

Analysts say mavacamten will bring in revenues of over $2 billion by 2026. Myokardia’s share price almost doubled when news of the acquisition broke.

The deal is the second-largest pharmaceutical acquisition in 2020 so far, behind Gilead Sciences’s $21 billion purchase of Immunomedics last month.


Legal advisor to Bristol-Myers Squibb: Kirkland & Ellis

Financial advisor to Bristol-Myers Squibb: Gordon Dyal & Co.

Legal advisor to MyoKardia: Goodwin

Financial advisor to MyoKardia: Centerview Partners, Guggenheim Securities

Read the full Special Report: USA: Global Powerhouse

In a world where the only thing that doesn't change is change itself, opportunities and risks are too obvious to ignore, and the legal market is no exception. Worth over $400 billion and one of the most profitable in the world, the U.S. legal industry is under fundamental transformation. Whether you're an in-house counsel or a law firm, only those with far-ranging sights, clear thoughts and quick action can survive and thrive.
Summary Interview: Prakash Melwani (Chief Investment Officer, Blackstone) AstraZeneca buys Alexion Pharmaceuticals for $39bn Salesforce buys Slack for $27.7bn S&P Global buys IHS Markit for $44bn The Home Depot re-buys HD Supply for $9.1 billion PNC buys BBVA's US arm for $11.6bn “External consultants bring more cost-efficiency and innovation than internal marketing teams” Advanced Micro Devices buys Xilinx for $35bn Leading the way: Kamala Harris makes history What would a Biden presidency mean for the US and the world?


Accenture's CEO and CFO interview by Leaders League Group

About us


Ce site utilise des cookies. En continuant la navigation, vous acceptez nos conditions d'utilisation des cookies.
Plus d'informations